Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: Type 2 Diabetes


Individuals Fulfilling Criteria for Type 2 Diabetes Rather Than LADA Display Transient Signs of Autoimmunity Preceding Diagnosis With Possible Clinical Implications: The HUNT Study

November 21st 2018

We demonstrate signs of transient, prediagnostic evidence of autoimmune activity in patients later diagnosed and classified as having type 2 diabetes. Compared with other participants with type 2 diabetes, this subgroup had earlier onset of diabetes and may have lower β-cell function with possible clinical implications (Diabetes Care)

Categories: News, Pathology
Tags: lada, Type 2 Diabetes

Categories: Pathology
Tags: lada, Type 2 Diabetes

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

November 19th 2018

In contrast to real-world data, there was no evidence of an improvement in all-cause and cardiovascular mortality in type 2 diabetes participants included in control arms of randomised clinical trials across 5 decades. Further studies should investigate whether and how dissimilarities in populations, procedures, and assessments of exposures and outcomes explain the differences between real-world setting and clinical trials (Acta Diabetologica)

Categories: News, Research
Tags: Type 2 Diabetes

Categories: Research
Tags: Type 2 Diabetes

Carbohydrate restriction for glycaemic control in Type 2 diabetes: a systematic review and meta‐analysis

November 15th 2018

There was no overall pooled effect on HbA1c in favour of restricting carbohydrate; however, restriction of carbohydrate to 50–130 g per day had beneficial effects on HbA1c in trials up to 6 months (Diabetic Medicine)

Categories: Diet, News
Tags: carbohydrate, glycaemic control, Type 2 Diabetes

Categories: Diet
Tags: carbohydrate, glycaemic control, Type 2 Diabetes

Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes

November 15th 2018

We concluded that recovery of the AIR could be obtained in T2DM patients of varying disease duration by short-term intensive insulin therapy and it could be conveniently estimated using posttreatment fasting plasma glucose and other fasting indicators (Journal of Diabetes Research)

Categories: News, Treatment
Tags: insulin, Type 2 Diabetes

Categories: Treatment
Tags: insulin, Type 2 Diabetes

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes

November 12th 2018

SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure (The Lancet)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

November 10th 2018

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure (NEJM)

Categories: Medication, News
Tags: dapagliflozin, DECLARE-TIMMI, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, DECLARE-TIMMI, Type 2 Diabetes

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

November 9th 2018

Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)

Categories: Cardiovascular, News
Tags: Linagliptin, renal risk, Type 2 Diabetes

Categories: Cardiovascular
Tags: Linagliptin, renal risk, Type 2 Diabetes

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)

November 8th 2018

Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)

Categories: Cardiovascular, News
Tags: renal biomarkers, Type 2 Diabetes

Categories: Cardiovascular
Tags: renal biomarkers, Type 2 Diabetes

Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross‐over trial

November 6th 2018

People with type 2 diabetes experienced improved postprandial and 24 h glycaemia and decreased blood pressure after 4 months of AA supplementation when compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and blood pressure control in people with type 2 diabetes (Diabetes, Obesity and Metabolism)

Categories: Diet, News
Tags: Ascorbic acid, Type 2 Diabetes

Categories: Diet
Tags: Ascorbic acid, Type 2 Diabetes

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

November 6th 2018

When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: DPP4, Type 2 Diabetes

Categories: Medication
Tags: DPP4, Type 2 Diabetes

Efficacy of a self-management education programme on patients with type 2 diabetes in primary care: A randomised controlled trial

November 6th 2018

HbA1c reductions are difficult to obtain in adequately controlled patients. On the other hand, raising awareness on one´s disease can increase disease control self-efficacy. This finding, accompanied by reduced medication consumption and healthcare use rates, highlights that usual care would be benefited by incorporating certain SDSMP aspects (Primary Care Diabetes)

Categories: Management, News
Tags: Type 2 Diabetes

Categories: Management
Tags: Type 2 Diabetes

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

November 6th 2018

Lixisenatide reduces progression of UACR in macroalbuminuric patients, and is associated with a lower risk of new-onset macroalbuminuria after adjustment for baseline and on-trial HbA 1c and other traditional renal risk factors (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: lixisenatide, Type 2 Diabetes

Categories: Medication
Tags: lixisenatide, Type 2 Diabetes

Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus

October 30th 2018

These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus (Hypertension)

Categories: Hypertension, News
Tags: creatinine, Type 2 Diabetes

Categories: Hypertension
Tags: creatinine, Type 2 Diabetes

Evaluation of the Long‐Term Cost‐Effectiveness of Once‐Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK

October 29th 2018

Compared with treatment with dulaglutide, once‐weekly semaglutide represents a cost‐effective option for treating people with T2DM not achieving glycaemic control on metformin in the UK, projected to both improve clinical outcomes and reduce costs (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: Dulaglutide, Type 2 Diabetes

Categories: Medication
Tags: Dulaglutide, Type 2 Diabetes

Development and validation of a risk prediction model for severe hypoglycemia in adult patients with type 2 diabetes

October 26th 2018

This 14-variable prediction model for SH events may be a useful tool to identify high-risk patients and guide prevention of SH in adult patients with T2DM  (Clinical Epidemiology)

Categories: Monitoring, News
Tags: hypoglycemia, Type 2 Diabetes

Categories: Monitoring
Tags: hypoglycemia, Type 2 Diabetes

Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial

October 25th 2018

Compared with CPT, IPT reduced HbA 1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes (The Lancet Diabetes & Endocrinology)

Categories: News, Treatment
Tags: periodontitis, Type 2 Diabetes

Categories: Treatment
Tags: periodontitis, Type 2 Diabetes

Self-monitoring of blood glucose provides no important benefit for most people with type 2 diabetes

October 24th 2018

The review supports current guideline recommendations that self-monitoring is not routinely used for people with type 2 diabetes controlled on diet or tablets (NIHR)

Categories: Monitoring, News
Tags: Type 2 Diabetes

Categories: Monitoring
Tags: Type 2 Diabetes

Long‐term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second‐line Type 2 diabetes mellitus treatment in a US Veterans Affairs population

October 23rd 2018

The results of the present study may inform decisions on whether to augment or discontinue metformin; when considering the long‐term risks, switching to a sulfonylurea appears unfavourable compared with other therapies. Instead, adding a thiazolidinedione to existing metformin therapy appears to be superior to adding or switching to a sulfonylurea (Diabetic Medicine)

Categories: Medication, News
Tags: metformin, sulfonylureas, Type 2 Diabetes

Categories: Medication
Tags: metformin, sulfonylureas, Type 2 Diabetes

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

October 21st 2018

In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes (Journal of Diabetes Research)

Categories: News, Treatment
Tags: insulin, Type 2 Diabetes, β-cell

Categories: Treatment
Tags: insulin, Type 2 Diabetes, β-cell

Effect of Health Information Technologies on Glycemic Control Among Patients with Type 2 Diabetes

October 18th 2018

Our meta-analysis shows that overall, HITs have favorable impact on glycemic control of patients with type 2 diabetes. On average, mobile-based interventions produce larger effects compared to other forms of approaches under review (Current Diabetes Reports)

Categories: Management, News
Tags: IT, Type 2 Diabetes

Categories: Management
Tags: IT, Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 34
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenSanofi DiabetesAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI cancer CGM closed-loop dapagliflozin DPP4 Dulaglutide Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microbiota microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy RYGB SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 Glycosmedia Partnership